Fang Xiaoqian
Department of pediatrics department, Dongyang People's Hospital, Dongyang, 322100, Zhejiang, China.
Sci Rep. 2025 May 23;15(1):18041. doi: 10.1038/s41598-025-03337-5.
To examine changes in peripheral blood complete blood count (CBC) parameters during acute Kawasaki disease(KD), compare immunoglobulin(IVIG)-sensitive and IVIG-resistant groups, and develop an IVIG resistance model. A retrospective review of clinical and lab data from 282 KD patients (2014-2024) was conducted. CBC parameters were collected at initial, pre-IVIG, and post-IVIG stages. The rank-sum test assessed parameter differences over time. Patients were categorized into IVIG-resistant (n = 29) and IVIG-sensitive (n = 253) groups. Univariate and multivariate logistic regression analyses identified IVIG resistance risk factors, resulting in four predictive models (A, B, C, and D) based on blood changes and clinical experience. The models' effectiveness was evaluated using receiver operating characteristic (ROC) curves, the Hosmer-Lemeshow test, and decision curve analysis, with the bootstrap(BS) method confirming performance. Significant differences were found in post-IVIG blood parameters, including white blood cell count (WBC), neutrophils, lymphocytes, eosinophils, hemoglobin, platelets, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and mean platelet volume to lymphocyte ratio (MPVLR), compared to pre-IVIG and initial CBC (P < 0.05). In IVIG-resistant patients, NLR, PLR, MPVLR, neutrophil percentage were higher, while lymphocyte percentage was lower than in IVIG-sensitive patients (P < 0.05). The resistant group also showed smaller changes in neutrophil percentages (△N) and lymphocyte percentages (△L). Area under the curve (AUC) values for BS-ROC curves were as follows: model A: 0.758 (95% CI: 0.636-0.878), model B: 0.917 (95% CI: 0.852-0.982), model C: 0.949 (95% CI: 0.909-0.978), and model D (NLR post-IVIG administration combined with △L): 0.910 (95% CI: 0.857-0.963). Hosmer-Lemeshow test P values for all four models were > 0.05. DCA indicated clinical value for all models, especially model C. Blood routine parameters in children with KD vary over time, and IVIG administration alters these parameters. We developed and validated four prediction models for IVIG resistance in KD patients using blood routine data. This indicates that ongoing monitoring of these parameters can predict IVIG resistance and enhance patient outcomes.
为了研究急性川崎病(KD)期间外周血全血细胞计数(CBC)参数的变化,比较免疫球蛋白(IVIG)敏感组和IVIG抵抗组,并建立IVIG抵抗模型。对282例KD患者(2014 - 2024年)的临床和实验室数据进行回顾性分析。在初始、IVIG治疗前和IVIG治疗后阶段收集CBC参数。秩和检验评估参数随时间的差异。将患者分为IVIG抵抗组(n = 29)和IVIG敏感组(n = 253)。单因素和多因素逻辑回归分析确定IVIG抵抗的危险因素,基于血液变化和临床经验得出四个预测模型(A、B、C和D)。使用受试者工作特征(ROC)曲线、Hosmer - Lemeshow检验和决策曲线分析评估模型的有效性,自助法(BS)确认模型性能。与IVIG治疗前和初始CBC相比,IVIG治疗后血液参数存在显著差异,包括白细胞计数(WBC)、中性粒细胞、淋巴细胞、嗜酸性粒细胞、血红蛋白、血小板、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)以及平均血小板体积与淋巴细胞比值(MPVLR)(P < 0.05)。在IVIG抵抗患者中,NLR、PLR、MPVLR、中性粒细胞百分比高于IVIG敏感患者,而淋巴细胞百分比低于IVIG敏感患者(P < 0.05)。抵抗组中性粒细胞百分比(△N)和淋巴细胞百分比(△L)的变化也较小。BS - ROC曲线的曲线下面积(AUC)值如下:模型A:0.758(95%CI:0.636 - 0.878),模型B:0.917(95%CI:0.852 - 0.982),模型C:0.949(95%CI:0.909 - 0.978),模型D(IVIG给药后NLR与△L联合):0.910(95%CI:0.857 - 0.963)。四个模型的Hosmer - Lemeshow检验P值均>0.05。决策曲线分析表明所有模型均具有临床价值,尤其是模型C。KD患儿的血常规参数随时间变化,IVIG给药会改变这些参数。我们使用血常规数据建立并验证了四个KD患者IVIG抵抗的预测模型。这表明持续监测这些参数可以预测IVIG抵抗并改善患者预后。